Your browser doesn't support javascript.
loading
Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer.
Alajati, Abdullah; Guccini, Ilaria; Pinton, Sandra; Garcia-Escudero, Ramon; Bernasocchi, Tiziano; Sarti, Manuela; Montani, Erica; Rinaldi, Andrea; Montemurro, Filippo; Catapano, Carlo; Bertoni, Francesco; Alimonti, Andrea.
Afiliação
  • Alajati A; Institute of Oncology Research (IOR), Bellinzona 6500, Switzerland; Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Guccini I; Institute of Oncology Research (IOR), Bellinzona 6500, Switzerland; Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Pinton S; Institute of Oncology Research (IOR), Bellinzona 6500, Switzerland; Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Garcia-Escudero R; Institute of Oncology Research (IOR), Bellinzona 6500, Switzerland; Molecular Oncology Unit, CIEMAT, Madrid 28040, Spain; Oncogenomics Unit, Institute of Biomed Research, Hospital "12 de Octubre", 28041 Madrid, Spain.
  • Bernasocchi T; Institute of Oncology Research (IOR), Bellinzona 6500, Switzerland.
  • Sarti M; Institute of Oncology Research (IOR), Bellinzona 6500, Switzerland; Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Montani E; Institute for Research in Biomedicine (IRB), Bellinzona 6500, Switzerland.
  • Rinaldi A; Institute of Oncology Research (IOR), Bellinzona 6500, Switzerland; Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Montemurro F; Investigative Clinical Oncology (INCO), Fondazione del Piemonte per l'Oncologia Candiolo Cancer Institute (IRCCS), Strada Provinciale 142, 10060 Candiolo, Italy.
  • Catapano C; Institute of Oncology Research (IOR), Bellinzona 6500, Switzerland; Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Bertoni F; Institute of Oncology Research (IOR), Bellinzona 6500, Switzerland; Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland.
  • Alimonti A; Institute of Oncology Research (IOR), Bellinzona 6500, Switzerland; Oncology Institute of Southern Switzerland (IOSI), Bellinzona 6500, Switzerland; Faculty of Biology and Medicine, University of Lausanne UNIL, Lausanne 1011, Switzerland. Electronic address: andrea.alimonti@ior.iosi.ch.
Cell Rep ; 11(4): 564-76, 2015 Apr 28.
Article em En | MEDLINE | ID: mdl-25892239
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Antígenos CD / Moléculas de Adesão Celular / Receptor ErbB-2 / Resistencia a Medicamentos Antineoplásicos / Carcinogênese / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cell Rep Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Suíça
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Antígenos CD / Moléculas de Adesão Celular / Receptor ErbB-2 / Resistencia a Medicamentos Antineoplásicos / Carcinogênese / Proteínas de Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cell Rep Ano de publicação: 2015 Tipo de documento: Article País de afiliação: Suíça